- Home
- STTK vs LUCD Comparison
STTK vs LUCD Comparison
Compare STTK & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LUCD
- Stock Information
- Founded
- STTK 2016
- LUCD 2018
- Country
- STTK United States
- LUCD United States
- Employees
- STTK N/A
- LUCD N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- STTK Health Care
- LUCD Health Care
- Exchange
- STTK Nasdaq
- LUCD Nasdaq
- Market Cap
- STTK 56.8M
- LUCD 51.6M
- IPO Year
- STTK 2020
- LUCD 2021
- Fundamental
- Price
- STTK $1.37
- LUCD $1.46
- Analyst Decision
- STTK Hold
- LUCD Strong Buy
- Analyst Count
- STTK 3
- LUCD 4
- Target Price
- STTK $2.00
- LUCD $3.63
- AVG Volume (30 Days)
- STTK 131.9K
- LUCD 680.2K
- Earning Date
- STTK 03-03-2025
- LUCD 03-24-2025
- Dividend Yield
- STTK N/A
- LUCD N/A
- EPS Growth
- STTK N/A
- LUCD N/A
- EPS
- STTK N/A
- LUCD N/A
- Revenue
- STTK $6,435,000.00
- LUCD $4,189,000.00
- Revenue This Year
- STTK $313.04
- LUCD $91.72
- Revenue Next Year
- STTK N/A
- LUCD $139.38
- P/E Ratio
- STTK N/A
- LUCD N/A
- Revenue Growth
- STTK 382.75
- LUCD 179.27
- 52 Week Low
- STTK $0.94
- LUCD $0.63
- 52 Week High
- STTK $11.76
- LUCD $1.63
- Technical
- Relative Strength Index (RSI)
- STTK 60.23
- LUCD 73.16
- Support Level
- STTK $1.21
- LUCD $1.34
- Resistance Level
- STTK $1.36
- LUCD $1.63
- Average True Range (ATR)
- STTK 0.10
- LUCD 0.14
- MACD
- STTK 0.01
- LUCD 0.04
- Stochastic Oscillator
- STTK 90.00
- LUCD 76.87
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.